{"id":17618,"date":"2021-07-01T15:56:42","date_gmt":"2021-07-01T13:56:42","guid":{"rendered":"https:\/\/idibell.cat\/en\/?page_id=17618"},"modified":"2025-01-14T10:39:44","modified_gmt":"2025-01-14T09:39:44","slug":"immunity-inflammation-and-cancer","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/cancer-area\/molecular-mechanisms-and-experimental-therapy-in-oncology-program-oncobell\/immunity-inflammation-and-cancer\/","title":{"rendered":"Immunity, inflammation and cancer"},"content":{"rendered":"\n

\n\t\tImmunity, inflammation and cancer\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

Our group is focused on three research lines. Regarding the exonuclease TREX2, our studies have been pioneering in unraveling the specific expression of TREX2 in keratinocytes and its key role in skin carcinogenesis and psoriasis. We also study how chromatin factors integrate extracellular signals into the nucleus to regulate gene expression and ultimately, influence cell fate and behavior. Our aim is to understand chromatin dynamics in cancer disease to find novel therapeutic interventions. Concerning oncolytic vaccinia viruses (VACV), our group is focused on improving their capacity to generate robust antitumor immune responses through an activation of an Immunogenic Cancer Cell Death (ICD) after infection. In addition, combination of these agents with other cancer immunotherapies are also explored in order to achieve a combinatory immunotherapy with a real potential to cure solid tumors.<\/p>\n

107<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"Immunity-inflammation-and-cancer\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t